Unum Therapeutics Inc (UMRX) stock is higher by 28.50% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives UMRX stock a score of 75 out of a possible 100.
That rank is influenced by a fundamental score of 97. In addition to the average rating from Wall Street analysts, UMRX stock has a mean target price of 6. This means analysts expect the stock to gain 125.56% over the next 12 months. UMRX's rank also includes a long-term technical score of 76. The short-term technical score for UMRX is 52.
What's Happening with UMRX Stock Today
Unum Therapeutics Inc (UMRX) stock has gained 11.09% while the S&P 500 is higher by 1.61% as of 2:40 PM on Monday, Sep 14. UMRX is higher by $0.26 from the previous closing price of $2.39 on volume of 398,528 shares. Over the past year the S&P 500 has risen 13.24% while UMRX is higher by 28.50%. UMRX lost -$0.75 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Unum Therapeutics Inc (UMRX) Stock.
